miR‑361‑5p regulates ovarian cancer cell proliferation and apoptosis by targeting TRAF3
Affiliations: Department of Obstetrics and Gynecology, Nantong Maternal and Child Health Care Hospital, Nantong, Jiangsu 226000, P.R. China, Clinical Laboratory, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430010, P.R. China
- Published online on: January 11, 2021 https://doi.org/10.3892/etm.2021.9632
Copyright: © Ling
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
An increasing body of evidence has demonstrated that the abnormal expression of microRNAs (miRNAs) participate in the development and progression of ovarian cancer. miR‑361‑5p has been reported to serve as a tumor suppressor or oncogene in a number of different human cancer types. In the current study, it was indicated that miR‑361‑5p was highly expressed in ovarian cancer tissues. Compared with human ovarian epithelial cells HOSEpiC, miR‑361‑5p was upregulated in ovarian cancer cell lines, including in ES‑2 and SKOV3 cells. The binding sites between TNF receptor‑associated factor 3 (TRAF3; a member of the TRAF family of cytoplasmic adaptor proteins) and miR‑361‑5p were predicted using TargetScan, and a dual luciferase reporter gene assay verified the result. Subsequently, a reverse transcription‑quantitative PCR assay and western blot assay indicated that TRAF3 was downregulated in ovarian cancer tissues and cell lines. It was demonstrated that miR‑361‑5p inhibitor significantly reduced the viability of SKOV3 cells and induced apoptosis. However, all changes were reversed by TRAF3 silencing. Furthermore, it was demonstrated that miR‑361‑5p inhibitor decreased the expression of p‑p65 in SKOV3 cells, indicating the inhibition of the NF‑kB signaling pathway. In conclusion, miR‑361‑5p may regulate the proliferation and apoptosis of ovarian cancer cells by targeting TRAF3. Therefore, targeting miR‑361‑5p may exhibit therapeutic potential in the treatment of ovarian cancer.